126 related articles for article (PubMed ID: 38636781)
41. The tyrosine kinase inhibitor nintedanib activates SHP-1 and induces apoptosis in triple-negative breast cancer cells.
Liu CY; Huang TT; Chu PY; Huang CT; Lee CH; Wang WL; Lau KY; Tsai WC; Chao TI; Su JC; Chen MH; Shiau CW; Tseng LM; Chen KF
Exp Mol Med; 2017 Aug; 49(8):e366. PubMed ID: 28798401
[TBL] [Abstract][Full Text] [Related]
42. Quantitative phosphoproteomics reveals genistein as a modulator of cell cycle and DNA damage response pathways in triple-negative breast cancer cells.
Fang Y; Zhang Q; Wang X; Yang X; Wang X; Huang Z; Jiao Y; Wang J
Int J Oncol; 2016 Mar; 48(3):1016-28. PubMed ID: 26783066
[TBL] [Abstract][Full Text] [Related]
43. A novel histone deacetylase (HDAC) inhibitor MHY219 induces apoptosis via up-regulation of androgen receptor expression in human prostate cancer cells.
Patra N; De U; Kim TH; Lee YJ; Ahn MY; Kim ND; Yoon JH; Choi WS; Moon HR; Lee BM; Kim HS
Biomed Pharmacother; 2013 Jun; 67(5):407-15. PubMed ID: 23583193
[TBL] [Abstract][Full Text] [Related]
44. HDAC inhibitors target IRS4 to enhance anti‑AR therapy in AR‑positive triple‑negative breast cancer.
He Y; Ma Y; Zhu Y; Zhang J; Zhao S; Zhang D; Xu D; Li Y; Tong Z; Zhao W
Int J Oncol; 2024 Mar; 64(3):. PubMed ID: 38214343
[TBL] [Abstract][Full Text] [Related]
45. Combination of the novel histone deacetylase inhibitor YCW1 and radiation induces autophagic cell death through the downregulation of BNIP3 in triple-negative breast cancer cells in vitro and in an orthotopic mouse model.
Chiu HW; Yeh YL; Wang YC; Huang WJ; Ho SY; Lin P; Wang YJ
Mol Cancer; 2016 Jun; 15(1):46. PubMed ID: 27286975
[TBL] [Abstract][Full Text] [Related]
46. MYC suppresses STING-dependent innate immunity by transcriptionally upregulating DNMT1 in triple-negative breast cancer.
Wu SY; Xiao Y; Wei JL; Xu XE; Jin X; Hu X; Li DQ; Jiang YZ; Shao ZM
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34321275
[TBL] [Abstract][Full Text] [Related]
47. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression.
Raha P; Thomas S; Thurn KT; Park J; Munster PN
Breast Cancer Res; 2015 Feb; 17(1):26. PubMed ID: 25848915
[TBL] [Abstract][Full Text] [Related]
48. A novel small molecule STAT3 inhibitor SLSI-1216 suppresses proliferation and tumor growth of triple-negative breast cancer cells through apoptotic induction.
Park SK; Byun WS; Lee S; Han YT; Jeong YS; Jang K; Chung SJ; Lee J; Suh YG; Lee SK
Biochem Pharmacol; 2020 Aug; 178():114053. PubMed ID: 32450253
[TBL] [Abstract][Full Text] [Related]
49. Preclinical Evaluation of a Novel Orally Available SRC/Raf/VEGFR2 Inhibitor, SKLB646, in the Treatment of Triple-Negative Breast Cancer.
Zheng MW; Zhang CH; Chen K; Huang M; Li YP; Lin WT; Zhang RJ; Zhong L; Xiang R; Li LL; Liu XY; Wei YQ; Yang SY
Mol Cancer Ther; 2016 Mar; 15(3):366-78. PubMed ID: 26721945
[TBL] [Abstract][Full Text] [Related]
50. Epigenetic reprogramming of epithelial mesenchymal transition in triple negative breast cancer cells with DNA methyltransferase and histone deacetylase inhibitors.
Su Y; Hopfinger NR; Nguyen TD; Pogash TJ; Santucci-Pereira J; Russo J
J Exp Clin Cancer Res; 2018 Dec; 37(1):314. PubMed ID: 30547810
[TBL] [Abstract][Full Text] [Related]
51. Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade.
Qin Y; Vasilatos SN; Chen L; Wu H; Cao Z; Fu Y; Huang M; Vlad AM; Lu B; Oesterreich S; Davidson NE; Huang Y
Oncogene; 2019 Jan; 38(3):390-405. PubMed ID: 30111819
[TBL] [Abstract][Full Text] [Related]
52. Targeting triple negative breast cancer with histone deacetylase inhibitors.
Fedele P; Orlando L; Cinieri S
Expert Opin Investig Drugs; 2017 Nov; 26(11):1199-1206. PubMed ID: 28952409
[TBL] [Abstract][Full Text] [Related]
53. Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway.
Fan Y; Li M; Ma K; Hu Y; Jing J; Shi Y; Li E; Dong D
Cancer Biol Ther; 2019; 20(5):617-632. PubMed ID: 30462562
[TBL] [Abstract][Full Text] [Related]
54. BRCA Mutational Status is a Promising Predictive Biomarker for Platinum- based Chemotherapy in Triple-Negative Breast Cancer.
Tazzite A; Jouhadi H; Benider A; Nadifi S
Curr Drug Targets; 2020; 21(10):962-973. PubMed ID: 32013831
[TBL] [Abstract][Full Text] [Related]
55. Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells.
Ha K; Fiskus W; Choi DS; Bhaskara S; Cerchietti L; Devaraj SG; Shah B; Sharma S; Chang JC; Melnick AM; Hiebert S; Bhalla KN
Oncotarget; 2014 Jul; 5(14):5637-50. PubMed ID: 25026298
[TBL] [Abstract][Full Text] [Related]
56. Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat.
Tate CR; Rhodes LV; Segar HC; Driver JL; Pounder FN; Burow ME; Collins-Burow BM
Breast Cancer Res; 2012 May; 14(3):R79. PubMed ID: 22613095
[TBL] [Abstract][Full Text] [Related]
57. Modulation of Estrogen α and Progesterone Receptors in Triple Negative Breast Cancer Cell Lines: The Effects of Vorinostat and Indole-3-Carbinol In Vitro.
Nouri Emamzadeh F; Word B; Cotton E; Hawkins A; Littlejohn K; Moore R; Miranda-Carbon G; Orish CN; Lyn-Cook B
Anticancer Res; 2020 Jul; 40(7):3669-3683. PubMed ID: 32620606
[TBL] [Abstract][Full Text] [Related]
58. Phosphorylated STAT3 (Tyr705) as a biomarker of response to pimozide treatment in triple-negative breast cancer.
Dees S; Pontiggia L; Jasmin JF; Mercier I
Cancer Biol Ther; 2020 Jun; 21(6):506-521. PubMed ID: 32164483
[TBL] [Abstract][Full Text] [Related]
59. Lippia origanoides extract induces cell cycle arrest and apoptosis and suppresses NF-κB signaling in triple-negative breast cancer cells.
Raman V; Fuentes Lorenzo JL; Stashenko EE; Levy M; Levy MM; Camarillo IG
Int J Oncol; 2017 Dec; 51(6):1801-1808. PubMed ID: 29075784
[TBL] [Abstract][Full Text] [Related]
60. ER alpha negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor.
Fan J; Yin WJ; Lu JS; Wang L; Wu J; Wu FY; Di GH; Shen ZZ; Shao ZM
J Cancer Res Clin Oncol; 2008 Aug; 134(8):883-90. PubMed ID: 18264725
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
